It can be challenging to differentiate severe primary IGF-I deficiency from other conditions of short stature. In this micro learning, expert paediatric endocrinologists from PE CONNECT share their knowledge of identifying and treating SPIGFD in practice.

You'll learn how to recognise the typical presentation of SPIGFD and how a combination of clinical assessment and biochemical analysis of the GH-IGF-I axis can support your diagnosis of this rare condition.

After watching the video, take the assessment to earn your CME credit.

 

Clinical Takeaways

  • Severe primary IGF-I deficiency (SPIGFD) generally presents as classical Laron syndrome, but non-classical cases with mild or moderate phenotypes should also be considered
  • An endocrine investigation should be conducted to assess the GH-IGF-I axis to ensure appropriate diagnosis
  • Diagnosis of severe primary IGF-I deficiency requires severe short stature, low serum IGF-I and normal or increased growth hormone secretion, as well as lack of other pathology
  • An early and correct diagnosis is essential to allow children to achieve their full growth potential with appropriate treatment
  • Be able to differentiate Severe Primary IGF-I deficiency (SPIGFD) from other conditions of short stature
  • Understand how to diagnose patients with SPIGFD based on clinical presentation and biochemical assessment of the GH-IGF axis
  • Have an awareness of the challenges related to diagnosis of SPIGFD patients

Prof. Philippe Backeljauw has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Prof. Philippe Backeljauw is a consultant for Novo Nordisk, Novartis/Sandoz, Tolmar Pharmaceuticals, Ascendis Pharma, BioMarin Pharmaceutical, Cavalry Biosciences and Ipsen, and currently receives research support from Novo Nordisk, Novartis and Ipsen

Prof. Peter Bang has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Prof. Peter Bang is a consultant for Ipsen and Lilly

It can be challenging to differentiate severe primary IGF-I deficiency from other conditions of short stature. In this micro learning, expert paediatric endocrinologists from PE CONNECT share their knowledge of identifying and treating SPIGFD in practice.

You'll learn how to recognise the typical presentation of SPIGFD and how a combination of clinical assessment and biochemical analysis of the GH-IGF-I axis can support your diagnosis of this rare condition.

After watching the video, take the assessment to earn your CME credit.

 

Clinical Takeaways

  • Severe primary IGF-I deficiency (SPIGFD) generally presents as classical Laron syndrome, but non-classical cases with mild or moderate phenotypes should also be considered
  • An endocrine investigation should be conducted to assess the GH-IGF-I axis to ensure appropriate diagnosis
  • Diagnosis of severe primary IGF-I deficiency requires severe short stature, low serum IGF-I and normal or increased growth hormone secretion, as well as lack of other pathology
  • An early and correct diagnosis is essential to allow children to achieve their full growth potential with appropriate treatment
  • Be able to differentiate Severe Primary IGF-I deficiency (SPIGFD) from other conditions of short stature
  • Understand how to diagnose patients with SPIGFD based on clinical presentation and biochemical assessment of the GH-IGF axis
  • Have an awareness of the challenges related to diagnosis of SPIGFD patients

Prof. Philippe Backeljauw has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Prof. Philippe Backeljauw is a consultant for Novo Nordisk, Novartis/Sandoz, Tolmar Pharmaceuticals, Ascendis Pharma, BioMarin Pharmaceutical, Cavalry Biosciences and Ipsen, and currently receives research support from Novo Nordisk, Novartis and Ipsen

Prof. Peter Bang has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Prof. Peter Bang is a consultant for Ipsen and Lilly

Programme summary
Share this programme
This educational programme is supported by an Independent Educational Grant from Ipsen
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Ipsen
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PE CONNECT

PE CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Ipsen.

Meet the experts Independent IME approved
Programme summary
  • clock Duration MIN
  • clock Language(s) flag
Share this programme
This educational programme is supported by an Independent Educational Grant from Ipsen
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Ipsen
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PE CONNECT

PE CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Ipsen.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
patient-support Patient Support
Oncology Hemato-oncology Pediatrics 
Personalised treatment in childhood cancer: A journey through NTRK fusion testing

Experts
Linet Menachery
Endorsed by
NTRKers ICAN international cancer advocacy network Biomarker Collaborative
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
patient-support Patient Support
Rare diseases 
Understanding narcolepsy

Persistent sleepiness: when to look closer

Experts
Prof. Yves Dauvilliers
Endorsed by
EU-NN ANC
eNAP
  • clock 2 MIN
  • calendar Jan 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Takeda
patient-support Patient Support

Episode

2

of 2

episode
Oncology Endocrinology Rare diseases 
Thriving beyond an EP-NEC diagnosis

Perspectives on treatment and care 

Experts
Jessica Thomas
Endorsed by
NET-Research-Foundation Minkhas mission
  • clock 4 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
patient-support Patient Support

Episode

1

of 2

episode
Oncology Endocrinology Rare diseases 
Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC)

Insights for patients and care partners 

Experts
Meredith Cummins
Endorsed by
INCA
NeuroEndocrine Cancer Australia Neuroendocrine Cancer Foundation NET-Research-Foundation
Neuroendocrine Cancer UK Minkhas mission
  • clock 5 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim